BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 2015;54:993-1025. [DOI: 10.1007/s40262-015-0282-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Malik S, Hamer R, Shabir S, Youssouf S, Morsy M, Rashid R, Waqar S, Ghouri N. Effects of fasting on solid organ transplant recipients during Ramadan - a practical guide for healthcare professionals. Clin Med (Lond) 2021;21:e492-8. [PMID: 34507933 DOI: 10.7861/clinmed.2021-0250] [Reference Citation Analysis]
2 Mac Guad R, Zaharan N, Chik Z, Mohamed Z, Peng N, Adnan W. Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplantation Proceedings 2016;48:81-7. [DOI: 10.1016/j.transproceed.2016.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
3 Chen L, Li C, Huo N, Mishuk AU, Hansen RA, Harris I, Kiptanui Z, Qian J. Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study. Curr Med Res Opin 2020;36:1533-40. [PMID: 32644886 DOI: 10.1080/03007995.2020.1793750] [Reference Citation Analysis]
4 Li J, Chen S, Qin X, Fu Q, Bi H, Zhang Y, Wang X, Liu L, Wang C, Huang M. Wuzhi Tablet ( Schisandra sphenanthera Extract) Is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who Are CYP3A5 Expressers: a Two-Phase Prospective Study. Drug Metab Dispos 2017;45:1114-9. [DOI: 10.1124/dmd.117.076737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
5 Bodnar-broniarczyk M, Pawiński T, Kunicki PK. Isotope–labeled versus analog internal standard in LC–MS/MS method for tacrolimus determination in human whole blood samples – A compensation of matrix effects. Journal of Chromatography B 2019;1104:220-7. [DOI: 10.1016/j.jchromb.2018.11.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
7 Vadcharavivad S, Saengram W, Phupradit A, Poolsup N, Chancharoenthana W. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies. Drugs 2019;79:1947-62. [PMID: 31713065 DOI: 10.1007/s40265-019-01217-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
9 Yau WP, Loh CW, Vathsala A. Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. Eur J Drug Metab Pharmacokinet 2019;44:481-92. [PMID: 30471066 DOI: 10.1007/s13318-018-0531-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sánchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, Calviño J, Serra N, Aladrén MJ, Cigarrán S, Manonelles A, Ramos A, Gómez G, González Posada JM, Andrés A, Beneyto I, Muñiz AL, Perelló M, Lauzurica R. Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study. Clin Transplant 2020;34:e13767. [PMID: 31815310 DOI: 10.1111/ctr.13767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Liu L, Li J, Zhao M, Xu H, Li L, Wang S. Loading of tacrolimus containing lipid based drug delivery systems into mesoporous silica for extended release. Asian Journal of Pharmaceutical Sciences 2016;11:751-9. [DOI: 10.1016/j.ajps.2016.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Prado-Velasco M, Borobia A, Carcas-Sansuan A. Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. Sci Rep 2020;10:7542. [PMID: 32371893 DOI: 10.1038/s41598-020-64189-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients. Int J Mol Sci 2018;19:E882. [PMID: 29547545 DOI: 10.3390/ijms19030882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Marquet P, Albano L, Woillard JB, Rostaing L, Kamar N, Sakarovitch C, Gatault P, Buchler M, Charpentier B, Thervet E, Cassuto E. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. Pharmacol Res 2018;129:84-94. [PMID: 29229354 DOI: 10.1016/j.phrs.2017.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ma TK, Chow KM, Cheng PM, Kwan BC, Leung CB, Li PK, Szeto CC. Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients. Hong Kong Journal of Nephrology 2016;19:1-6. [DOI: 10.1016/j.hkjn.2016.03.002] [Reference Citation Analysis]
16 Kim CS, Mathew AP, Vasukutty A, Uthaman S, Joo SY, Bae EH, Ma SK, Park IK, Kim SW. Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis. J Nanobiotechnology 2021;19:109. [PMID: 33865397 DOI: 10.1186/s12951-021-00857-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tenório JR, Tuma M, Martins F, Ortega KL, Cristelli M, Gallottini M. Diagnosis and management of oral ulcerations associated with mycophenolate mofetil in kidney transplantation. Spec Care Dentist 2020;40:605-10. [PMID: 32950040 DOI: 10.1111/scd.12522] [Reference Citation Analysis]
18 Dheer D, Gupta R, Singh D, Magotra A, Singh G, Gupta PN, Shankar R. Hyaluronic Acid-Tacrolimus Bioconjugate: Synthesis, Characterization, and Pharmacokinetic Investigation of an Acid-Responsive Macromolecular Prodrug. ACS Appl Bio Mater 2019;2:4728-36. [DOI: 10.1021/acsabm.9b00423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Jouve T, Rostaing L, Malvezzi P. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. Expert Opinion on Drug Safety 2017;16:845-55. [DOI: 10.1080/14740338.2017.1328051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Stifft F, Vandermeer F, Neef C, van Kuijk S, Christiaans MHL. A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts. Eur J Clin Pharmacol 2020;76:685-93. [DOI: 10.1007/s00228-019-02814-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Marquet P, Bedu A, Monchaud C, Saint-marcoux F, Rérolle J, Etienne I, Kamar N, Moulin B, Cassuto E, Essig M, Woillard J. Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. Therapeutic Drug Monitoring 2018;40:285-91. [DOI: 10.1097/ftd.0000000000000503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
22 Gantar K, Škerget K, Mochkin I, Bajc A. Meeting Regulatory Requirements for Drugs with a Narrow Therapeutic Index: Bioequivalence Studies of Generic Once-Daily Tacrolimus. Drug Healthc Patient Saf 2020;12:151-60. [PMID: 32982466 DOI: 10.2147/DHPS.S256455] [Reference Citation Analysis]
23 Kamar N, Cassuto E, Piotti G, Govoni M, Ciurlia G, Geraci S, Poli G, Nicolini G, Mariat C, Essig M, Malvezzi P, Le Meur Y, Garrigue V, Del Bello A, Rostaing L. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Adv Ther 2019;36:462-77. [PMID: 30552587 DOI: 10.1007/s12325-018-0855-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
24 Fleming JN, Posadas Salas MA, Taber DJ. Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Ther Drug Monit 2020;42:415-20. [PMID: 31913864 DOI: 10.1097/FTD.0000000000000722] [Reference Citation Analysis]
25 Stephens A, Nidetz R, Mesyngier N, Chung MT, Song Y, Fu J, Kurabayashi K. Mass-producible microporous silicon membranes for specific leukocyte subset isolation, immunophenotyping, and personalized immunomodulatory drug screening in vitro. Lab Chip 2019;19:3065-76. [PMID: 31389447 DOI: 10.1039/c9lc00315k] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Franco A, Más-Serrano P, Balibrea N, Rodriguez D, Javaloyes A, Díaz M, Gascón I, Ramon-Lopez A, Perez-Contreras J, Selva J, Nalda-Molina R. Envarsus, a novelty for transplant nephrologists: Observational retrospective study. Nefrologia (Engl Ed) 2019;39:506-12. [PMID: 30850218 DOI: 10.1016/j.nefro.2018.11.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Brooks E, Tett SE, Isbel NM, Staatz CE. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? Clin Pharmacokinet 2016;55:1295-335. [DOI: 10.1007/s40262-016-0396-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
28 Rancic N, Vavic N, Obrencevic K, Pilipovic F, Dragojevic-Simic V. Tacrolimus Utilization and Expenditure in Serbia. Front Public Health 2017;5:291. [PMID: 29164097 DOI: 10.3389/fpubh.2017.00291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Gao GF, Ashtikar M, Kojima R, Yoshida T, Kaihara M, Tajiri T, Shanehsazzadeh S, Modh H, Wacker MG. Predicting drug release and degradation kinetics of long-acting microsphere formulations of tacrolimus for subcutaneous injection. J Control Release 2021;329:372-84. [PMID: 33271202 DOI: 10.1016/j.jconrel.2020.11.055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
30 Gelder TV, Etsouli O, Moes DJ, Swen JJ. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes (Basel) 2020;11:E1205. [PMID: 33076474 DOI: 10.3390/genes11101205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Tanaka R, Suzuki Y, Watanabe H, Fujioka T, Hirata K, Shin T, Ando T, Ono H, Tatsuta R, Mimata H, Maruyama T, Itoh H. Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. Clin Transl Sci 2021. [PMID: 34058078 DOI: 10.1111/cts.13065] [Reference Citation Analysis]
32 Jorgenson MR, Descourouez JL, Brady BL, Bowman L, Hammad S, Kaiser TE, Laub MR, Melaragno JI, Park JM, Chandran MM. Alternatives to immediate release tacrolimus in solid organ transplant recipients: When the gold standard is in short supply. Clin Transplant 2020;34. [DOI: 10.1111/ctr.13903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Gustavsen MT, Midtvedt K, Lønning K, Jacobsen T, Reisaeter AV, De Geest S, Andersen MH, Hartmann A, Åsberg A. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. Transpl Int 2019;32:614-25. [DOI: 10.1111/tri.13412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
34 Dheer D, Jyoti, Gupta PN, Shankar R. Tacrolimus: An updated review on delivering strategies for multifarious diseases. European Journal of Pharmaceutical Sciences 2018;114:217-27. [DOI: 10.1016/j.ejps.2017.12.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
35 Heits N, Keserovic D, Mund N, Ehmke N, Bernsmeier A, Hendricks A, Gunther R, Witt K, Becker T, Braun F. Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy. Transplant Direct 2017;3:e146. [PMID: 28405602 DOI: 10.1097/TXD.0000000000000658] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Zhang Z, Zhang Y, Yu H, Rong S, Gao H, Meng L, Dai J, Pan H, Chang D. Spherical carrier amplification strategy for electrochemical immunosensor based on polystyrene-gold nanorods @L-cysteine/MoS2 for determination of tacrolimus. Talanta 2020;220:121321. [DOI: 10.1016/j.talanta.2020.121321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Woillard J, Debord J, Monchaud C, Saint-marcoux F, Marquet P. Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. Clin Pharmacokinet 2017;56:1491-8. [DOI: 10.1007/s40262-017-0533-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
38 Niel O, Bastard P. Artificial intelligence improves estimation of tacrolimus area under the concentration over time curve in renal transplant recipients. Transpl Int 2018;31:940-1. [DOI: 10.1111/tri.13271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
39 Okumi M, Unagami K, Furusawa M, Kakuta Y, IIzuka J, Takagi T, Shirakawa H, Shimizu T, Omoto K, Inui M, Ishida H, Tanabe K. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial. Clin Transplant 2018;32:e13423. [PMID: 30318624 DOI: 10.1111/ctr.13423] [Reference Citation Analysis]
40 Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 2017;13:1225-36. [PMID: 29084469 DOI: 10.1080/17425255.2017.1395413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
41 Bezerra LS, Santos-Veloso MAO, Oliveira SBL, Dias AAP, Carvalho-Filho ÂT, Gonzaga-Neto PP, Melo PSV. Tacrolimus therapeutic efficacy in post-liver transplant patients with Cytochrome P450 3A5 (CYP3A5) genetic polymorphisms. Rev Col Bras Cir 2020;47:e20202384. [PMID: 32578817 DOI: 10.1590/0100-6991e-20202384] [Reference Citation Analysis]
42 Kikuchi M, Shigeta K, Tanaka M, Takasaki S, Akiba M, Oishi H, Sado T, Matsuda Y, Noda M, Okada Y, Mano N, Yamaguchi H. Estimation of Blood Sirolimus Concentration Based on Tacrolimus Concentration/Dose Normalized by Body Weight Ratio in Lung Transplant Patients. Ther Drug Monit 2019;41:615-9. [PMID: 31033859 DOI: 10.1097/FTD.0000000000000649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Henin E, Govoni M, Cella M, Laveille C, Piotti G. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations. Adv Ther 2021;38:5317-32. [PMID: 34515977 DOI: 10.1007/s12325-021-01905-5] [Reference Citation Analysis]
44 Piotti G, Cremaschi E, Maggiore U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol 2017;30:53-61. [DOI: 10.1007/s40620-016-0316-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
45 Martial LC, Verstegen RH, Cornelissen EA, Aarnoutse RE, Schreuder MF, Brüggemann RJ. A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. J Pharm Pharmacol 2016;68:1366-72. [PMID: 27669677 DOI: 10.1111/jphp.12639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
46 Nanga TM, Doan TTP, Marquet P, Musuamba FT. Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. Br J Clin Pharmacol 2019;85:2793-823. [PMID: 31471970 DOI: 10.1111/bcp.14110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
47 Saengram W, Vadcharavivad S, Poolsup N, Chancharoenthana W. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:1249-1260. [PMID: 29961086 DOI: 10.1007/s00228-018-2512-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
48 Schijvens AM, van Hesteren FHS, Cornelissen EAM, Bootsma-Robroeks CMHHT, Brüggemann RJM, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R. The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatr Nephrol 2019;34:507-15. [PMID: 30374607 DOI: 10.1007/s00467-018-4117-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
49 Prytuła AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathôt RA. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet 2016;55:1129-43. [PMID: 27138785 DOI: 10.1007/s40262-016-0390-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
50 Torabi J, Campbell A, Ajaimy M, Rocca JP, Graham JA. Utilization of LCP-Tacrolimus (Envarsus XR) in Simultaneous Pancreas and Kidney Transplant Recipients. Ochsner J 2018;18:190-2. [PMID: 30275776 DOI: 10.31486/toj.18.0011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]